ClinicalTrials.gg

Program

AP31969

A development code.

Its studies are mostly in Atrial Fibrillation · Arrhythmias, Cardiac, led by Acesion Pharma.

Furthest: phase 2, since Nov 25, 20253 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Acesion Pharma31 open or runningphase 2since Nov 25, 2025Sep 27, 2023May 2027phase 2 · NCT07267949

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2023First study: phase 1 study in Arrhythmias, CardiacFirst studyNCT06066099 · 92 enrolled · Netherlands
  2. Nov 25, 2025Phase 2 study in Atrial FibrillationPhase 2 reachedNCT07267949 · 200 planned · Bulgaria, Denmark, Germany and more
  3. Feb 27, 2026Phase 1 study in Healthy ParticipantsNCT07449390 · 28 enrolled · United States

Ahead

  1. May 2027Primary completion: phase 2 study in Atrial FibrillationNCT07267949

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07449390Healthy Participants · United States1CompletedMay 9, 202628
NCT07267949Atrial Fibrillation · Bulgaria, Denmark, Germany and more2RecruitingMay 2027200
NCT06066099Arrhythmias, Cardiac · Netherlands1CompletedMar 14, 202592

How it is read

Names in the registry

  • “AP31969”, 3 entries

Codes read as this program: AP31969.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.